Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus

LAURA MAGNANO, HECTOR ENRÍQUEZ, JORDI ESTEVE, RICARD CERVERA and GERARD ESPINOSA
The Journal of Rheumatology September 2014, 41 (9) 1895-1896; DOI: https://doi.org/10.3899/jrheum.140080
LAURA MAGNANO
Department of Hematology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HECTOR ENRÍQUEZ
Department of Autoimmune Diseases;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JORDI ESTEVE
Department of Hematology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RICARD CERVERA
Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GERARD ESPINOSA
Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gespino@clinic.ub.es
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

REFERENCES

  1. 1.↵
    1. Newman K,
    2. Owlia MB,
    3. Al-Hemaidi I,
    4. Akhtari M
    . Management of immune cytopenias in patients with systemic lupus erythematosus - old and new. Autoimmun Rev 2013;12:784–91.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kuter DJ,
    2. Bussel JB,
    3. Newland A,
    4. Baker RI,
    5. Lyons RM,
    6. Wasser J,
    7. et al.
    Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013;161:411–23.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Rodeghiero F,
    2. Stasi R,
    3. Giagounidis A,
    4. Viallard JF,
    5. Godeau B,
    6. Pabinger I,
    7. et al.
    Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia (ITP): a pooled analysis of 13 clinical trials. Eur J Haematol 2013;91:423–36.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Bussel JB,
    2. Cheng G,
    3. Saleh MN,
    4. Psaila B,
    5. Kovaleva L,
    6. Medded B,
    7. et al.
    Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237–47.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Katsutani S,
    2. Tomiyama Y,
    3. Kimura A,
    4. Miyakawa Y,
    5. Okamoto S,
    6. Okoshi Y,
    7. et al.
    Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Haematol 2013;98:323–30.
    OpenUrlCrossRef
  6. 6.↵
    1. Gonzalez-Nieto JA,
    2. Martin-Suarez I,
    3. Quattrino S,
    4. Ortiz-Lopez E,
    5. Muñoz-Beamud FR,
    6. Colchero-Fernandez J,
    7. et al.
    The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab. Lupus 2011;20:1321–3.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Alkaabi JK,
    2. Alkindi S,
    3. Riyami NA,
    4. Zia F,
    5. Balla LM,
    6. Balla SM
    . Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus. Lupus 2012;21:1571–4.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Tomov S,
    2. Lazarchick J,
    3. Self SE,
    4. Bruner ET,
    5. Budisavljevic MN
    . Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim. Lupus 2013;22:504–9.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Cela I,
    2. Miller IJ,
    3. Katz RS,
    4. Rizman A,
    5. Shammo JM
    . Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus. Clin Adv Hematol Oncol 2010;8:806–9.
    OpenUrlPubMed
  10. 10.↵
    1. Gudbrandsdottir S,
    2. Frederiksen H,
    3. Hasselbalch H
    . Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. Platelets 2012;23:423–9.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Thota S,
    2. Kistangari G,
    3. Daw H,
    4. Spiro T
    . Immune thrombocytopenia in adults: an update. Cleve Clin J Med 2012;79:641–50.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Kuwana K,
    2. Kaburaki J,
    3. Okazaki Y,
    4. Miyazaki H,
    5. Ikeda Y
    . Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology 2006;45:851–4.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Gernsheimer TB,
    2. George JN,
    3. Aledort LM,
    4. Tarantino MD,
    5. Sunkara U,
    6. Matthew Guo D,
    7. et al.
    Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010; 8:1372–82.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 9
1 Sep 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus
LAURA MAGNANO, HECTOR ENRÍQUEZ, JORDI ESTEVE, RICARD CERVERA, GERARD ESPINOSA
The Journal of Rheumatology Sep 2014, 41 (9) 1895-1896; DOI: 10.3899/jrheum.140080

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus
LAURA MAGNANO, HECTOR ENRÍQUEZ, JORDI ESTEVE, RICARD CERVERA, GERARD ESPINOSA
The Journal of Rheumatology Sep 2014, 41 (9) 1895-1896; DOI: 10.3899/jrheum.140080
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Case 1
    • Case 2
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
  • COVID-19 and IgA Vasculitis
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire